JPS6287516A - 悪性腫瘍の生体外での処置法 - Google Patents

悪性腫瘍の生体外での処置法

Info

Publication number
JPS6287516A
JPS6287516A JP61241199A JP24119986A JPS6287516A JP S6287516 A JPS6287516 A JP S6287516A JP 61241199 A JP61241199 A JP 61241199A JP 24119986 A JP24119986 A JP 24119986A JP S6287516 A JPS6287516 A JP S6287516A
Authority
JP
Japan
Prior art keywords
cisplatin
nifedipine
tumor
cells
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP61241199A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0357081B2 (cg-RX-API-DMAC7.html
Inventor
ケネス　ブイ　ホン
ジヨン　デイ　テイラー
ジエームズ　エム　オノダ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UEEN STATE UNIV
Original Assignee
UEEN STATE UNIV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UEEN STATE UNIV filed Critical UEEN STATE UNIV
Publication of JPS6287516A publication Critical patent/JPS6287516A/ja
Publication of JPH0357081B2 publication Critical patent/JPH0357081B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
JP61241199A 1985-10-10 1986-10-09 悪性腫瘍の生体外での処置法 Granted JPS6287516A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/786,321 US4906646A (en) 1983-03-31 1985-10-10 Method and composition for the treatment of tumors by administering a platinum coordination compound and a calcium channel blocker compound of the dihydropyridine class
US786321 1985-10-10

Publications (2)

Publication Number Publication Date
JPS6287516A true JPS6287516A (ja) 1987-04-22
JPH0357081B2 JPH0357081B2 (cg-RX-API-DMAC7.html) 1991-08-30

Family

ID=25138262

Family Applications (1)

Application Number Title Priority Date Filing Date
JP61241199A Granted JPS6287516A (ja) 1985-10-10 1986-10-09 悪性腫瘍の生体外での処置法

Country Status (5)

Country Link
US (1) US4906646A (cg-RX-API-DMAC7.html)
EP (1) EP0221382A1 (cg-RX-API-DMAC7.html)
JP (1) JPS6287516A (cg-RX-API-DMAC7.html)
CA (1) CA1278518C (cg-RX-API-DMAC7.html)
DE (1) DE221382T1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5130303A (en) * 1988-08-02 1992-07-14 Nissan Chemical Industries Ltd. Drug effect-enhancing agent for antitumor drug
JP2008510730A (ja) * 2004-08-20 2008-04-10 ユニバーシテイ・オブ・バージニア・パテント・フアウンデーシヨン Ｔ型カルシウムチャネルブロッカーおよび疾患の治療

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5720937A (en) * 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
US4985558A (en) * 1988-07-28 1991-01-15 Nikken Chemicals Co., Ltd. 1,4-dihydropyridine derivative
JP2850376B2 (ja) * 1988-08-02 1999-01-27 日産化学工業株式会社 抗癌剤薬効増強剤
GB9119983D0 (en) * 1991-09-19 1991-11-06 Erba Carlo Spa Dihydropyridine derivatives useful in antitumor therapy
FR2686879B1 (fr) * 1992-02-05 1994-03-18 Adir Cie Nouveaux composes de 1,4-dihydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant.
US6749853B1 (en) * 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US20040127884A1 (en) * 1994-12-12 2004-07-01 Omeros Corporation Vascular irrigation solution and method for inhibition of pain, inflammation, spasm and restenosis
US6268377B1 (en) * 1998-09-28 2001-07-31 Merck & Co., Inc. Method for treating androgen-related conditions
JP4776843B2 (ja) 1999-10-01 2011-09-21 イムノゲン インコーポレーティッド 免疫複合体及び化学療法剤を用いる癌治療用組成物及び方法
US20040167165A1 (en) * 2003-01-16 2004-08-26 Geetha Shankar Methods of treating conditions associated with an Edg-7 receptor
US20100222406A1 (en) * 2007-09-11 2010-09-02 University Of Virginia Patent Foundation T Type Calcium Channel Blockers and the Treatment of Diseases
WO2009132454A1 (en) * 2008-04-28 2009-11-05 Neuromed Pharmaceuticals Ltd. Di-t-butylphenyl piperazines as calcium channel blockers
CN102781316B (zh) 2010-03-01 2016-07-06 陶制药有限责任公司 癌症诊断和成像
US9361667B2 (en) 2010-08-27 2016-06-07 Sony Corporation Image processing apparatus and method
WO2019008516A2 (en) * 2017-07-03 2019-01-10 Menri Group Ltd. TREATMENT OF CANCER WITH DIHYDROPYRIDINES
WO2019147089A1 (ko) * 2018-01-26 2019-08-01 재단법인 대구경북첨단의료산업진흥재단 칼슘 채널 억제제 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4177263A (en) * 1972-02-28 1979-12-04 Research Corporation Anti-animal tumor method
CH605550A5 (cg-RX-API-DMAC7.html) * 1972-06-08 1978-09-29 Research Corp
US4419351A (en) * 1977-06-03 1983-12-06 Research Corporation Platinum-dioxopyrimidine complexes
US4234499A (en) * 1979-03-07 1980-11-18 Engelhard Minerals & Chemicals Corporation Cis-diammireplatinum(II) organophosphate complexes
DE3379107D1 (en) * 1982-06-03 1989-03-09 Pierrel Spa Hydroxyimino and alkoxyimino derivatives of 1,4-dihydropyridine, process for the preparation thereof and pharmaceutical composition therefrom
US4690935A (en) * 1983-03-31 1987-09-01 Wayne State University Inhibition of tumor growth and metastasis with calcium channel blocker compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5130303A (en) * 1988-08-02 1992-07-14 Nissan Chemical Industries Ltd. Drug effect-enhancing agent for antitumor drug
JP2008510730A (ja) * 2004-08-20 2008-04-10 ユニバーシテイ・オブ・バージニア・パテント・フアウンデーシヨン Ｔ型カルシウムチャネルブロッカーおよび疾患の治療

Also Published As

Publication number Publication date
DE221382T1 (de) 1987-10-15
EP0221382A1 (en) 1987-05-13
JPH0357081B2 (cg-RX-API-DMAC7.html) 1991-08-30
US4906646A (en) 1990-03-06
CA1278518C (en) 1991-01-02

Similar Documents

Publication Publication Date Title
RU2587013C2 (ru) Комбинированная химиотерапия
JP2005008534A (ja) 抗癌剤及び癌の治療方法
CZ290120B6 (cs) Sdruľená kompozice paclitaxelu, docetaxelu nebo jejich analogu
US20190262267A1 (en) Pharmaceutical solution having a toxicity-reducing effect for antitumor drugs, and pharmaceutical composition comprising same
US20010018445A1 (en) Pharmaceutical composition for the treatment of hepatocellular carcinoma
US4906646A (en) Method and composition for the treatment of tumors by administering a platinum coordination compound and a calcium channel blocker compound of the dihydropyridine class
US6063814A (en) Phorbol esters as anti-neoplastic and white blood cell elevating agents
EP0774255B1 (en) Use of ursolic acid for the manufacture of a medicament for suppressing metastasis
BG107843A (bg) Ефективно антитуморно лечение
EP1201247B1 (en) Treatment of metastatic renal cell carcinoma
EP0344880A2 (en) Pharmaceutical compositions with anti-cancer activity
RU2730998C2 (ru) Композиции форболовых эфиров и способы их применения для лечения или уменьшения продолжительности цитопении
US6297245B1 (en) Cisplatin and folic acid administered to treat breast cancer
JP2024125140A (ja) アズブジンと化学療法剤とを含む抗腫瘍医薬組成物
US20030133994A1 (en) Method for treating cancer having greater efficacy and reduced adverse effects
WO2008066783A2 (en) Therapeutic materials and methods
JPH07116031B2 (ja) 制癌剤
KR20170045751A (ko) 고령이나 말기의 암환자를 치료 또는 경감하기 위한 의약 조성물
JPH11508566A (ja) リファブチンを含む抗細菌相乗性組成物
AU2002251763B2 (en) Method for treating cancer
WO2002007719A1 (en) Use of estramustine phosphate in the treatment of bone metastasis
CN111544580B (zh) 一种抗癌症的药物组合物
Gasparini et al. Continuous cisplatin infusion in combination with vincristine and high-dose methotrexate for advanced osteogenic sarcoma
CN111544579B (zh) 一种抗癌症的药物组合物
US20020131997A1 (en) Method for treating hematologic disorders with water insoluble 20 (S)-camptothecin